Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 9/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531524 | 1.00 | NTSR2 (0.45) | NTSR2NTSR1BACE1CTSDFURIN | |
| SCHEMBL10381547 | 0.96 | FURIN (0.48) | NTSR2NTSR1BACE1CTSDFURIN | |
| SCHEMBL10381550 | 0.96 | FURIN (0.48) | NTSR2NTSR1BACE1CTSDFURIN | |
| SCHEMBL29368320 | 0.93 | BACE1 (0.51) | NTSR2NTSR1BACE1CTSDBACE2 | |
| SCHEMBL20818872 | 0.92 | GSR (0.51) | GSRDPP8DPP9DPP7ERAP2 | |
| SCHEMBL29531457 | 0.92 | GSR (0.51) | GSRDPP8DPP9DPP7ERAP2 | |
| SCHEMBL8013829 | 0.92 | GSR (0.51) | GSRDPP8DPP9DPP7ERAP2 | |
| SCHEMBL4270981 | 0.91 | FOLH1 (0.48) | GSRDPP8DPP9DPP7ERAP2 | |
| SCHEMBL4270994 | 0.91 | FOLH1 (0.48) | GSRDPP8DPP9DPP7ERAP2 | |
| SCHEMBL29387347 | 0.91 | BACE1 (0.51) | BACE1CTSDFURINPCSK6BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731237-A1 | COMBINATION THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA | Stealth BioTherapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260008810-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250319073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4608387-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | Stealth BioTherapeutics Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168423-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3723783-B1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220265615-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson?s Disease, Parkinson?s Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-08-25 | — | — | US | disclosed |
| CN-114466656-A | Peptidomimetic compounds (R) -2-amino-N- ((S) -1- (((S) -5-amino-1- (3-benzyl-1, 2, 4-oxadiazol-5-yl) pentyl) amino) -3- (4-hydroxy-2, 6-xylyl) -1-oxopropan-2-yl) -5-guanidinopentanamide in the treatment of neurodegenerative disorders | 康德生物医疗有限公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3986401-A1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Stealth BioTherapeutics Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220041654-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | STEALTH BIOTHERAPEUTICS INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041654-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | MTPN, TFAM, PDF | NTSR2 1060/4885NTSR1 722/4885BACE1 3601/4885 |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | NTSR2 572/4885NTSR1 604/4885BACE1 2616/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | NTSR2 2347/4885NTSR1 996/4885BACE1 1097/4885 |
| US-20250319073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES | HTT, TTR, HYPK | NTSR2 260/4885NTSR1 288/4885BACE1 333/4885 |
| US-20220265615-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson?s Disease, Parkinson?s Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | NLN, TARDBP, PARK7 | NTSR2 2102/4885NTSR1 2239/4885BACE1 235/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | NTSR2 310/4885NTSR1 237/4885BACE1 3564/4885 |
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | NTSR2 1223/4885NTSR1 1394/4885BACE1 1747/4885 |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | NLN, TARDBP, PARK7 | NTSR2 2231/4885NTSR1 2343/4885BACE1 261/4885 |
| US-20260008810-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | UQCRC1, HADHA, HADHB | NTSR2 1764/4885NTSR1 1194/4885BACE1 3615/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | NTSR2 1292/4885NTSR1 1307/4885BACE1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.